Applied DNA seeks NY bird flu test approval
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 26 2025
0mins
Source: SeekingAlpha
Approval Submission: Applied DNA Clinical Labs has submitted a validation package to the New York State Department of Health for approval of a PCR-based assay to detect and subtype the influenza A (H5) virus or H5N1.
Stock Performance: Following the announcement, Applied DNA Sciences' stock increased by 3.8% in premarket trading, reaching $2.18.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
